STOCK TITAN

AIM ImmunoTech Inc - AIM STOCK NEWS

Welcome to our dedicated news page for AIM ImmunoTech (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AIM ImmunoTech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AIM ImmunoTech's position in the market.

Rhea-AI Summary
AIM ImmunoTech Inc. will present at the MedInvest Biotech & Pharma Investor Conference on April 3rd, 2024. Thomas K. Equels, CEO, will discuss company updates and meet with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
AIM ImmunoTech Inc. to discuss Q4/FY2023 results in a conference call on April 2, 2024, led by CEO Thomas K. Equels and Scientific Officer Christopher McAleer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
earnings
-
Rhea-AI Summary
AIM ImmunoTech Inc. announces positive data analysis from a study on Ampligen in treating advanced pancreatic cancer. The study shows immune-stimulatory properties of TLR-3 activation, enhancing anti-tumor immunity through dendritic cell-mediated T cell responses. Ampligen treatment correlates with improved clinical outcomes and decreased expression of immune checkpoints. The company aims to expand Ampligen's application to various solid tumor types, with ongoing clinical trials to evaluate its effectiveness in pancreatic cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
Rhea-AI Summary
AIM ImmunoTech Inc. announces the publication of the CEO Corner segment featuring Thomas Equels, discussing corporate overview, business outlook, and the AIM opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.46%
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech Inc. releases CEO Corner segment discussing Advanced Recurrent Ovarian Cancer and clinical development milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) will present at the Virtual Investor Lunch Break event with CEO Tom Equels on March 20th, discussing the company's business outlook and opportunities. The live video webcast will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
Rhea-AI Summary
AIM ImmunoTech Inc. launches CEO Corner featuring Thomas K Equels to provide additional perspective on press releases, corporate developments, and pipeline progress. The platform aims to connect directly with stockholders, offering expanded insights on clinical trials and corporate advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech Inc. highlights progress in Ampligen clinical development programs for various indications, including Post-COVID conditions, pancreatic cancer, and ovarian cancer. Recent accomplishments include positive results in the AMP-518 study and the DURIPANC study. The company emphasizes building upon scientific success and anticipates significant value for stockholders. Upcoming milestones include interim results for advanced recurrent ovarian cancer and final dataset for Post-COVID conditions in Q1 and Q2 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
AIM ImmunoTech Inc. announced the dosing of the first subject in a Phase 1b/2 clinical trial combining Ampligen with Imfinzi for late-stage pancreatic cancer treatment. The study is expected to be completed within six months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
clinical trial
Rhea-AI Summary
AIM ImmunoTech Inc. announces positive topline results from Phase 2 study of Ampligen in treating Post-COVID fatigue. Initial analysis shows lower fatigue levels in Ampligen group at multiple time points. The Six-Minute Walk Test also reveals a higher impact of Ampligen on distance traveled compared to placebo. Safety results indicate Ampligen is generally well-tolerated with no severe adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.64%
Tags
clinical trial covid-19
AIM ImmunoTech Inc

NYSE:AIM

AIM Rankings

AIM Stock Data

23.00M
44.36M
9.19%
8.52%
0.87%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Ocala

About AIM

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as